Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease

Publisher： Bentham Science Publishers

E-ISSN： 1874-6128|8|3|235-240

ISSN： 1874-6098

Source： Current Aging Science, Vol.8, Iss.3, 2015-11, pp. : 235-240

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Galantamine in Alzheimer’s Disease

By Lyseng-Williamson K.A.   Plosker G.L.  

Disease Management & Health Outcomes, Vol. 11, Iss. 2, 2003-01 ,pp. : 125-128

Adis International

Access to resources Recommend Favorite

Vitamin C, Aging and Alzheimer’s Disease

By Monacelli Fiammetta   Acquarone Erica   Giannotti Chiara   Borghi Roberta   Nencioni Alessio  

Nutrients, Vol. 9, Iss. 7, 2017-06 ,pp. : 670-670

MDPI

Access to resources Recommend Favorite

Utility-based Quality of Life Measures in Alzheimer’s Disease

By Naglie Gary   Tomlinson George   Tansey Catherine   Irvine Jane   Ritvo Paul   Black Sandra   Freedman Morris   Silberfeld Michel   Krahn Murray  

Quality of Life Research, Vol. 15, Iss. 4, 2006-05 ,pp. : 631-643

Springer Publishing Company

Access to resources Recommend Favorite

Health Status in Patients with Alzheimer’s Disease: An Investigation of Inter-rater Agreement

By Novella JL.   Boyer F.   Jochum C.   Jovenin N.   Morrone I.   Jolly D.   Bakchine S.   Blanchard F.  

Quality of Life Research, Vol. 15, Iss. 5, 2006-06 ,pp. : 811-819

Springer Publishing Company

Access to resources Recommend Favorite

Melatonin Decreases Levels of S100&bgr; and NF&kgr;B, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease

By  

Current Aging Science, Vol. 6, Iss. 2, 2013-07 ,pp. : 142-149

Bentham Science Publishers

Access to resources Recommend Favorite